Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Metro Healthcare BhdXKLS:0329 59 EV-to-EBITDA is 12.12 as of Aug. 14, 2026, which is 85% below its 10-year median of 82.26. GuruFocus rates XKLS:0329 with a GF Score™ of 59/100 and a GF Value™ of RM0.31 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 511 Healthcare Providers & Services companies, Metro Healthcare Bhd ranks worse than 55.19% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Metro Healthcare Bhd's enterprise value is RM181.45 Mil.
Metro Healthcare Bhd's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was RM14.97 Mil. Therefore, Metro Healthcare Bhd's EV-to-EBITDA for today is 12.12.
The historical rank and industry rank for Metro Healthcare Bhd's EV-to-EBITDA or its related term are showing as below:
XKLS:0329'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.2 Med: 82.26 Max: 169.87
Current: 12.13
During the past 11 years, the highest EV-to-EBITDA of Metro Healthcare Bhd was 169.87. The lowest was 8.20. And the median was 82.26.
XKLS:0329's EV-to-EBITDA is ranked worse than 55.19% of 511
companies
in the Healthcare Providers & Services industry
Industry Median: 10.76
vs XKLS:0329: 12.13
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Metro Healthcare Bhd (XKLS:0329) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Metro Healthcare Bhd's PE Ratio (TTM) for today is calculated as:
Metro Healthcare Bhd's share price for today is RM0.22.
Metro Healthcare Bhd's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM0.006.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Metro Healthcare Bhd's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:0329 vs HCA, THC, DVA: EV-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Metro Healthcare Bhd's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metro Healthcare Bhd EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Metro Healthcare Bhd's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Metro Healthcare Bhd's EV-to-EBITDA falls into.
Metro Healthcare Bhd's current Enterprise Value is RM181.45 Mil.
Metro Healthcare Bhd's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM14.97 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metro Healthcare Bhd (XKLS:0329) has a EV-to-EBITDA of 12.12 as of Aug. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Metro Healthcare Bhd. This is 85% below median its historical median of 82.26. Over the past decade, Metro Healthcare Bhd's EV-to-EBITDA has ranged from 8.20 to 169.87. According to the industry distribution chart, Metro Healthcare Bhd ranks #282 out of 511 companies in the Healthcare Providers & Services industry, placing it in the top 55.2%.
Is Metro Healthcare Bhd's EV-to-EBITDA too high?
Metro Healthcare Bhd's current EV-to-EBITDA of 12.12 is 85% below median its 10-year median of 82.26. Over the past 10 years, this metric has ranged from a low of 8.20 to a high of 169.87. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.76. Metro Healthcare Bhd's value of 12.12 is 12.6% above this industry median. Based on the distribution chart, Metro Healthcare Bhd ranks #282 out of 511 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Metro Healthcare Bhd has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Metro Healthcare Bhd's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Metro Healthcare Bhd ranks #282 out of 511 companies for EV-to-EBITDA. This places Metro Healthcare Bhd in the lower half of its industry. The industry median EV-to-EBITDA is 10.76. Metro Healthcare Bhd's value of 12.12 is 12.6% above this benchmark. Historically, Metro Healthcare Bhd's own EV-to-EBITDA has ranged from 8.20 to 169.87 over the past decade. While the company's 10-year median is 82.26 vs. the industry median of 10.76, Metro Healthcare Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.76, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Metro Healthcare Bhd's current EV-to-EBITDA of 12.12 is 12.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Metro Healthcare Bhd. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metro Healthcare Bhd's current EV-to-EBITDA is 12.12, which is 85% below median its own 10-year median of 82.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metro Healthcare Bhd stock overvalued right now?
Based on GuruFocus' analysis, Metro Healthcare Bhd (XKLS:0329) is currently considered Modestly Undervalued. The stock's GF Value™ is RM0.31, compared to a current price of RM0.22 — trading 29% below its estimated fair value. The current EV-to-EBITDA is 12.12, which is 85% below median its 10-year median of 82.26 and 12.6% above the Healthcare Providers & Services industry median of 10.76. Metro Healthcare Bhd's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Metro Healthcare Bhd (XKLS:0329), the current EV-to-EBITDA is 12.12 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Metro Healthcare Bhd (XKLS:0329) Overvalued in 2026?
Based on GuruFocus' analysis, Metro Healthcare Bhd stock appears to be undervalued.
The current stock price of RM0.22 is trading 29% below its estimated GF Value™ of RM0.31.
GuruFocus considers Metro Healthcare Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:0329:
EV-to-EBITDA: 12.12 (85% below median its 10-year median of 82.26)
GF Value™: RM0.31 vs. price of RM0.22 (29% below fair value)
Industry Position: 12.6% above the Healthcare Providers & Services median (#282 of 511)
No single metric tells the full story. See the XKLS:0329 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Metro Healthcare Bhd is engaged in the provision of women healthcare services. The company offers various services such as obstetrics, gynecology impatient services, and diagnostic medical imaging services. It also provides semen analysis, intracytoplasmic sperm injection, blastocyst culture, assisted hatching, frozen embryo transfer, preimplantation genetic screening, and infertility consultation services. The company serves patients in Malaysia. The firm's business segment includes O&G healthcare services, Complementary services, and Hospital services.
59GF Score
Get the complete analysis for XKLS:0329
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0329 has been successfully added to your 
